Biotech | October 26, 2021
Biological E to receive US $ 50 million to boost Covid-19 vaccine capacity
Support from DFC will help produce one billion vaccine doses by the end of 2022
Support from DFC will help produce one billion vaccine doses by the end of 2022
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
